Rafferty Asset Management’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.07M | Sell |
76,412
-29,462
| -28% | -$412K | ﹤0.01% | 753 |
|
|
2025
Q1 | $1.43M | Sell |
105,874
-67,086
| -39% | -$904K | 0.01% | 663 |
|
|
2024
Q4 | $3.32M | Buy |
172,960
+82,309
| +91% | +$1.58M | 0.01% | 501 |
|
|
2024
Q3 | $2.06M | Sell |
90,651
-54,324
| -37% | -$1.24M | 0.01% | 628 |
|
|
2024
Q2 | $1.89M | Sell |
144,975
-263,912
| -65% | -$3.43M | 0.01% | 660 |
|
|
2024
Q1 | $7.16M | Buy |
408,887
+206,396
| +102% | +$3.61M | 0.03% | 375 |
|
|
2023
Q4 | $4.41M | Sell |
202,491
-59,805
| -23% | -$1.3M | 0.02% | 473 |
|
|
2023
Q3 | $4.02M | Buy |
262,296
+18,282
| +7% | +$280K | 0.02% | 445 |
|
|
2023
Q2 | $5.81M | Buy |
244,014
+67,088
| +38% | +$1.6M | 0.03% | 378 |
|
|
2023
Q1 | $4.5M | Buy |
176,926
+59,913
| +51% | +$1.52M | 0.03% | 406 |
|
|
2022
Q4 | $3.42M | Buy |
117,013
+59,222
| +102% | +$1.73M | 0.03% | 455 |
|
|
2022
Q3 | $1.19M | Buy |
+57,791
| New | +$1.19M | 0.01% | 621 |
|